EXPOSURE-RESPONSE (E-R) ANALYSIS OF OVERALL SURVIVAL (OS) FOR NIVOLUMAB IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Feng, Y. [1 ]
Bajaj, G. [1 ]
Agrawal, S. [1 ]
Wang, X. [1 ]
Bello, A. [1 ]
Roy, A. [1 ]
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-098
引用
收藏
页码：S56 / S57
页数：2
相关论文
共 50 条
  • [1] EXPOSURE- RESPONSE (E-R) ANALYSIS OF OVERALL SURVIVAL (OS) FOR NIVOLUMAB IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC).
    Feng, Y.
    Bajaj, G.
    Agrawal, S.
    Wang, X.
    Bello, A.
    Roy, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S7 - S7
  • [2] Ipilimumab Exposure-Response (E-R) Analysis of Overall Survival (OS) in Patients with Advanced Melanoma
    Vezina, Heather E.
    Feng, Yan
    Roy, Amit
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S28 - S28
  • [3] Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Rogado, J.
    Pacheco-Barcia, V.
    Fenor De la Maza, M. D.
    Serra, J. M.
    Toquero, P.
    Vera, B.
    Obispo, B.
    Mondejar, R.
    Ballesteros, A.
    Donnay, O.
    Colomer, R.
    Sanchez-Torres, J. M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1915 - S1916
  • [4] NIVOLUMAB EXPOSURE-RESPONSE (E-R) ANALYSIS FOR CLINICAL DEVELOPMENT OF NIVOLUMAB IN ADVANCED REFRACTORY SQUAMOUS NON-SMALL CELL LUNG CANCER.
    Feng, Y.
    Wang, X.
    Agrawal, S.
    Lestini, B.
    Park, J.
    Roy, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S7 - S7
  • [5] NIVOLUMAB EXPOSURE-RESPONSE (E-R) ANALYSIS FOR CLINICAL DEVELOPMENT OF NIVOLUMAB IN ADVANCED REFRACTORY SQUAMOUS NON-SMALL CELL LUNG CANCER.
    Feng, Y.
    Wang, X.
    Agrawal, S.
    Lestini, B.
    Park, J.
    Roy, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S57 - S58
  • [6] Exposure-Response (E-R) Analysis of Progression Free Survival (PFS) for Nivolumab in Combination with Ipilimumab in Patients with Previously Untreated Advanced Melanoma
    Feng, Yan
    Wang, Xiaoning
    Statkevich, Paul
    Roy, Amit
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S67 - S67
  • [7] Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer
    Rodier, Thomas
    Puszkiel, Alicja
    Cardoso, Evelina
    Balakirouchenane, David
    Narjoz, Celine
    Arrondeau, Jennifer
    Fallet, Vincent
    Khoudour, Nihel
    Guidi, Monia
    Vidal, Michel
    Decleves, Xavier
    Csajka, Chantal
    Alexandre, Jerome
    Cadranel, Jacques
    Fabre, Elizabeth
    Wislez, Marie
    Goldwasser, Francois
    Blanchet, Benoit
    [J]. PHARMACEUTICS, 2022, 14 (09)
  • [8] Time trends in overall survival (OS) gain in advanced non-small-cell lung cancer (NSCLC).
    Saad, Everardo D.
    Buyse, Marc E.
    Jassem, Jacek
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
    Antonia, Scott J.
    Borghaei, Hossein
    Ramalingam, Suresh S.
    Horn, Leora
    De Castro Carpeno, Javier
    Pluzanski, Adam
    Burgio, Marco A.
    Garassino, Marina
    Chow, Laura Q. M.
    Gettinger, Scott
    Crino, Lucio
    Planchard, David
    Butts, Charles
    Drilon, Alexander
    Wojcik-Tomaszewska, Joanna
    Otterson, Gregory A.
    Agrawal, Shruti
    Li, Ang
    Penrod, John R.
    Brahmer, Julie
    [J]. LANCET ONCOLOGY, 2019, 20 (10): : 1395 - 1408
  • [10] NIVOLUMAB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): SURVIVAL AND CLINICAL ACTIVITY BY SUBGROUP ANALYSIS
    Brahmer, Julie R.
    Horn, Leora
    Gandhi, Leena
    Spigel, David R.
    Antonia, Scott J.
    Rizvi, Naiyer A.
    Powderly, John D.
    Heist, Rebecca S.
    Carvajal, Richard D.
    Jackman, David M.
    Sequist, Lecia V.
    Smith, David C.
    Leming, Philip D.
    Topalian, Suzanne L.
    Hodi, Stephen
    Snzol, Mario
    Harbison, Christopher T.
    Kollia, Gerogia D.
    Gupta, Ashok
    Gettinger, Scott N.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 157 - 157
12345